Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Anti-HIV activity demonstrated for Teijin's antioxidant

July 10, 1998

French group develops new inhibitors of HIV-1 protease dimerization

July 10, 1998

AMD-3100: a potent chemokine CXCR4 antagonist enters clinical testing

July 10, 1998

Anti-HIV peptide T-22 acts as a CXCR4 receptor antagonist

July 10, 1998

Enzo discovery paves the way for antisense therapy of AIDS

July 10, 1998

Chiron updates HIV product development

July 10, 1998

An overview of antiviral intervention strategies for HIV therapy

July 10, 1998

AMD-3465, a selective CXCR4 antagonist with potent anti-HIV activity

July 9, 1998

Lodenosine phase I data supports combination studies

July 9, 1998

Japanese investigators study HIV protease inhibitor with activity in drug-resistant virus

July 9, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...